Replies to post #233513 on Biotech Values

[DewDiligence]

ENTA—Good point. In the near future, most primary-care venues will likely be equipped with point-of-care tests to distinguish between: a) flu; b) RSV; c) COVID-19; and d) unknown. This, in turn, will considerably increase the addressable market for an RSV treatment early in the course of the disease.

[DewDiligence]

(Bullish_for ENTA)—ABT launches_4-in-1_test_for COVID/RSV/flu-A/flu-B:

https://finance.yahoo.com/news/abbott-receives-fda-eua-laboratory-140000497.html

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test. This is an important tool because these viruses have similar symptoms but require different treatment approaches.

…The Alinity m Resp-4-Plex test can be conducted with one swab specimen (anterior nasal or nasopharyngeal) collected by a healthcare provider or an anterior nasal swab specimen self-collected at a healthcare location from individuals suspected by their provider of respiratory viral infection consistent with COVID-19. Test will run on Abbott's Alinity m system — the company's most advanced high-volume laboratory molecular instrument. Alinity m uses Polymerase Chain Reaction (PCR) technology, which is known for its high sensitivity in detecting infectious diseases.

This is not a point-of-care test (i.e. it requires that samples be sent to a lab), but it’s nevertheless an opening for increased diagnosis of RSV.

ABT’s 4-in-1 test already has a CE Mark for ex-US use.